CTLA-4 Inhibitors Pipeline Analysis 2024: EMA, PDMA, FDA Approvals, Clinical Trials, Therapies, Mechanism Of Action, Route Of Administration, And Comp...
Source: menafn.com
Akeso Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Akeso Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Akeso Inc Today - Breaking & Trending Today
Summit Therapeutics Inc. Announces Phase III Clinical Trial, HARMONI-2 or AK112-303 Met its Primary Endpoint of Progression-Free Survival
Summit Therapeutics Inc. announced the Phase III clinical trial, HARMONI-2 or AK112-303, met its primary endpoint of progression-free survival . HARMONI-2 evaluated monotherapy ivonescimab against...
Source: marketscreener.com
Head to Head Review: Universe Pharmaceuticals (NYSE:UPC) & Summit Therapeutics (NASDAQ:SMMT)
Summit Therapeutics (NASDAQ:SMMT – Get Free Report) and Universe Pharmaceuticals (NYSE:UPC – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, analyst recommendations, dividends, earnings and profitability. Profitability This table compares Summit Therapeutics and Universe […]
Source: dailypolitical.com
Akeso, Inc.'s New Cancer Drug Wins China Approval
Akeso, Inc. (HK:9926) has released an update. Akeso, Inc. has announced that its novel drug ivonescimab, designed for advanced lung cancer patients...
Source: biztoc.com
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2024
HARMONi and HARMONi-3 Enrollment Continues Promising Intracranial Anti-Tumor Activity and Safety Data Featured at the 2024 European Lung Cancer Congress with Ivonescimab Alone or Combined with...
Source: marketscreener.com